<DOC>
	<DOCNO>NCT01146561</DOCNO>
	<brief_summary>Tanezumab effective reduce pain associate chronic pancreatitis .</brief_summary>
	<brief_title>Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis</brief_title>
	<detailed_description>On 23 Dec 2010 FDA impose clinical halt anti-NGF compound due safety reason , ie , case osteonecrosis occur relation anti-NGF compound another company . All indication exception Cancer Pain affect result termination study respective indication . Recruitment Study A4091044 stop effective 27 Dec 2010 . Two patient recruit far receive dos follow safety LSLV 22 Mar 2011 .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<criteria>Adult male female Written inform consent Diagnosis chronic pancreatitis base image study Persistent abdominal pain due chronic pancreatitis Qualifying pain score pretreatment period Willing comply study visit schedule study requirement include woman childbearing potential male patient female partner childbearing potential , use 2 form birth control Pregnant woman , lactate mother , woman suspect pregnant woman wish become pregnant course study Chronic pancreatitis complication pancreatic cancer acute pancreatic duct obstruction Pancreatic surgery , lithotripsy endoscopist decompression within 3 month History alcoholism ( within 1 year screening ) concurrent alcohol abuse History cancer past year Significant cardiac disease within 6 month History , diagnosis sign symptom significant neurologic disease Disqualifying laboratory value include Hepatitis B C , HIV drug test Other medical condition may interfere study endpoint safety patient determine Investigator Known history rheumatoid arthritis Avascular necrosis bone History trauma major joint Evidence osteoarthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>